- Trial Phase
- Approved - Generic
- Time to Market
- Already launched in India (March 2026) and Canada (May 2026), but supply halted until ~October 2026 due to API impurity. US market entry not expected until patent exclusivity ends ~2031-2032.
- Why 4/10
- Semaglutide is already approved and marketed by Dr. Reddy's in India and Canada (no pending PDUFA/pivotal readout). The next hard catalyst is the expected resumption of commercial supply in late October/early November 2026, after an API impurity halt. Since this is an already-commercialized product at a diversified company ($3.63B total revenue), there is no make-or-break binary; the score reflects that semaglutide is a major growth driver but not a single-asset binary.
Watch for Dr. Reddy's API remediation progress and the late-October 2026 supply restart timeline. The supply halt halved the FY27 production target from 12M to 6-7M pens and erased ~$678M in market cap. Any update on resolving the impurity issue, regulatory findings, or competitive dynamics (Apotex, USV) could move shares. US market entry (2031-2032 patent expiry) is the long-term prize but too distant to trade on now.
Price Chart
Executive Summary
Semaglutide is the blockbuster GLP-1 drug behind Novo Nordisk's Ozempic, Wegovy, and Rybelsus — a class generating tens of billions in annual sales. Dr. Reddy's Laboratories (NYSE: RDY) was the first generic to enter the Canadian market (April 2026) and launched its own semaglutide injection and oral tablet (branded Obeda) in India. However, on July 9, 2026, Dr. Reddy's suspended production after detecting an API impurity, slashing its FY27 supply target from 12M to 6-7M pens and wiping ~$678M from its market cap. Semaglutide is a very large commercial opportunity for generic manufacturers as patents expire globally, but near-term execution risk at Dr. Reddy's is significant.
How It Works
Semaglutide mimics a natural hormone called GLP-1 that your body releases after eating. It tells your pancreas to release more insulin (lowering blood sugar), tells your brain you're full (reducing appetite), and slows how fast food leaves your stomach. It's a once-weekly injection (Ozempic/Wegovy) or daily pill (Rybelsus) used for type 2 diabetes and chronic weight management.
Trial Status
Dr. Reddy's generic semaglutide injection received Health Canada Notice of Compliance on April 28, 2026 (first G7 country to approve a generic semaglutide) and launched commercially on May 15, 2026. The oral version (Obeda) launched in India on May 20, 2026. However, on July 9, 2026, the company halted production and supply after detecting an out-of-specification impurity in the API, expecting disruption until at least late October 2026.
The Two-Sided Case
Upcoming Catalysts
- Supply resumption timeline — Dr. Reddy's expects commercial supply to restart in late October / early November 2026; any delays or acceleration will move shares.
- API investigation outcome — details on the impurity root cause and regulatory findings (India's DCGI, Health Canada) could affect reputation and restart timing.
- Potential US market entry pathway — while 2031-2032 is the patent horizon, partnership, settlement, or licensing developments with Novo Nordisk could shift the timeline.
- Quarterly earnings — next Dr. Reddy's results will show the revenue impact of the semaglutide supply halt and updated guidance.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
DR REDDYS LABORATORIES LTD 6-K RDY ·Originating report